Evidence map›Paper›PMID 30565180›Full record

ArticleAdvances in therapy2019

Short-Term Assessment of Intravitreal Dexamethasone Implant Using Enhanced-Depth Image Optical Coherence Tomography and Optical Coherence Tomography Angiography in Patients with Retinal Vascular Diseases.

Angelo Maria Minnella, Matteo Federici, Valeria Pagliei, Angela Lanza, Gloria Gambini, Carmela Grazia Caputo, Benedetto Falsini, Aldo Caporossi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Angelo Maria MinnellaInstitute of Ophthalmology, Università Cattolica del Sacro Cuore, Rome, Italy. aminnella59@gmail.com.
Matteo FedericiDepartment of Ophthalmology, Bambino Gesù IRCCS Children's Hospital, Rome, Italy.
Valeria PaglieiInstitute of Ophthalmology, Università Cattolica del Sacro Cuore, Rome, Italy.
Angela LanzaOspedale Cristo Re, Rome, Italy.
Gloria GambiniInstitute of Ophthalmology, Università Cattolica del Sacro Cuore, Rome, Italy.
Carmela Grazia CaputoFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Benedetto FalsiniInstitute of Ophthalmology, Università Cattolica del Sacro Cuore, Rome, Italy.
Aldo CaporossiInstitute of Ophthalmology, Università Cattolica del Sacro Cuore, Rome, Italy.
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale Cristo Re · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the short-term efficacy and safety of intravitreal dexamethasone implant (IDI) in patients with macular oedema associated with diabetic retinopathy (DR) and retinal vein occlusion (RVO) using enhanced-depth image optical coherence tomography (EDI-OCT) and to estimate the effect of dexamethasone on the choroid and the retinal vascular network using OCT angiography (OCTA).

methodsFifteen eyes in 15 patients with macular oedema secondary to diabetes (DR, n = 8) or retinal vein occlusion (RVO, n = 7) were treated with intravitreal injection of sustained-release IDI. Primary efficacy end points were changes in best corrected visual acuity and central macular thickness (CMT). Secondary end points were changes in choroidal thickness and choroidal and retinal vascular networks as determined by OCTA.

resultsCMT was significantly reduced from baseline by 3 h after injection (p < 0.01) and improved further during the 3-month follow-up. Visual acuity improvement was consistent with CMT reduction. No alterations in IOP or systemic side effects were observed. OCTA showed improvement from baseline in terms of decreased number and size of cysts and restoration of the retinal vascular network; flow choroidal thickness did not change significantly. CMT and visual acuity variations were similar in the two groups.

conclusionsCMT reduced as early as 3 h after the injection of IDI, with further reduction during follow-up. Choroidal thickness was unchanged, whereas the vascular retinal network improved from baseline to the end of study. Both EDI-OCT and OCTA were useful in demonstrating the early beneficial effects of IDI on the macula and the perifoveal vascular network.

fundingThe article processing charges, the open access fee and the medical writing and editorial assistance was funded by Allergan.

Indexed as

AgedAngiographyDexamethasoneDiabetic RetinopathyDrug ImplantsFemaleGlucocorticoidsHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedRetinal Vein OcclusionTomography, Optical CoherenceVisual AcuityDexamethasoneDrug ImplantsGlucocorticoidsCentral retinal thicknessDiabetic macular oedemaEnhanced-depth image optical coherence tomographyInnovative biotechnologyMacular oedemaOCT angiographyOphthalmologyRetinal vein occlusionSpectral domain OCTSustained release intravitreal dexamethasone implant

Identifiers

PMID30565180
PMCPMC6824342
OpenAlexW2903847391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.